Lower Urinary Tract Symptoms in Myasthenia Gravis

It remains uncertain to what extent lower urinary tract (LUT) symptom (LUTS) is a comorbidity of myasthenia gravis (MG). We prospectively administered a LUTS questionnaire devised for detecting neurogenic pelvic organ dysfunction (not validated) in an MG group and a healthy control group and compare...

Full description

Bibliographic Details
Main Authors: Fuyuki Tateno, Ryuji Sakakibara, Yosuke Aiba
Format: Article
Language:English
Published: Karger Publishers 2021-07-01
Series:Case Reports in Neurology
Subjects:
Online Access:https://www.karger.com/Article/FullText/514825
_version_ 1818729439248252928
author Fuyuki Tateno
Ryuji Sakakibara
Yosuke Aiba
author_facet Fuyuki Tateno
Ryuji Sakakibara
Yosuke Aiba
author_sort Fuyuki Tateno
collection DOAJ
description It remains uncertain to what extent lower urinary tract (LUT) symptom (LUTS) is a comorbidity of myasthenia gravis (MG). We prospectively administered a LUTS questionnaire devised for detecting neurogenic pelvic organ dysfunction (not validated) in an MG group and a healthy control group and compared the results. The MG group comprised 21 patients: 15 women and 6 men, with age range 22–73 (mean 47) years, illness duration range 0.2–8 (mean 3.5) years, median Myasthenia Gravis Foundation of America (MGFA) grade 2, all walking independently. Therapies included thymectomy in 17, predonisolone 5–20 mg/day in 10, and pyridostigmine bromide 60–180 mg/day in 9 patients. The control group, who were undergoing an annual health survey, comprised 235 consecutive subjects: 120 women and 115 men, with age range 30–69 (mean 48) years. The questionnaire had 9 questions. Each question was scored from 0 (none) to 3 (severe) with an additional quality of life (QOL) index scored from 0 (satisfied) to 3 (extremely dissatisfied). Statistical analysis was made using Student’s t test. Compared with the control subjects, the frequency of LUTSs in the MG patients was significantly higher for daytime frequency (43%; p < 0.01), nocturia (24%; p < 0.01), and urinary incontinence (43%; p < 0.05). The LUTS-related QOL index for the MG patients was significantly higher for MG patients as a whole than that for all control patients (29%) (p < 0.05). In conclusion, our study results showed that MG patients had significantly more LUTSs (overactive bladder) than healthy control subjects and had worse LUTS-related QOL; therefore, amelioration of LUTS in MG is important.
first_indexed 2024-12-17T22:45:54Z
format Article
id doaj.art-91e68cca1ec84105881e379ba72700ec
institution Directory Open Access Journal
issn 1662-680X
language English
last_indexed 2024-12-17T22:45:54Z
publishDate 2021-07-01
publisher Karger Publishers
record_format Article
series Case Reports in Neurology
spelling doaj.art-91e68cca1ec84105881e379ba72700ec2022-12-21T21:29:48ZengKarger PublishersCase Reports in Neurology1662-680X2021-07-0113249049810.1159/000514825514825Lower Urinary Tract Symptoms in Myasthenia GravisFuyuki Tateno0Ryuji Sakakibara1Yosuke Aiba2Neurology, Internal Medicine, Sakura Medical Center, Toho University, Sakura, JapanNeurology, Internal Medicine, Sakura Medical Center, Toho University, Sakura, JapanNeurology, Internal Medicine, Sakura Medical Center, Toho University, Sakura, JapanIt remains uncertain to what extent lower urinary tract (LUT) symptom (LUTS) is a comorbidity of myasthenia gravis (MG). We prospectively administered a LUTS questionnaire devised for detecting neurogenic pelvic organ dysfunction (not validated) in an MG group and a healthy control group and compared the results. The MG group comprised 21 patients: 15 women and 6 men, with age range 22–73 (mean 47) years, illness duration range 0.2–8 (mean 3.5) years, median Myasthenia Gravis Foundation of America (MGFA) grade 2, all walking independently. Therapies included thymectomy in 17, predonisolone 5–20 mg/day in 10, and pyridostigmine bromide 60–180 mg/day in 9 patients. The control group, who were undergoing an annual health survey, comprised 235 consecutive subjects: 120 women and 115 men, with age range 30–69 (mean 48) years. The questionnaire had 9 questions. Each question was scored from 0 (none) to 3 (severe) with an additional quality of life (QOL) index scored from 0 (satisfied) to 3 (extremely dissatisfied). Statistical analysis was made using Student’s t test. Compared with the control subjects, the frequency of LUTSs in the MG patients was significantly higher for daytime frequency (43%; p < 0.01), nocturia (24%; p < 0.01), and urinary incontinence (43%; p < 0.05). The LUTS-related QOL index for the MG patients was significantly higher for MG patients as a whole than that for all control patients (29%) (p < 0.05). In conclusion, our study results showed that MG patients had significantly more LUTSs (overactive bladder) than healthy control subjects and had worse LUTS-related QOL; therefore, amelioration of LUTS in MG is important.https://www.karger.com/Article/FullText/514825myasthenia gravislower urinary tract symptomquality of lifeoveractive bladder
spellingShingle Fuyuki Tateno
Ryuji Sakakibara
Yosuke Aiba
Lower Urinary Tract Symptoms in Myasthenia Gravis
Case Reports in Neurology
myasthenia gravis
lower urinary tract symptom
quality of life
overactive bladder
title Lower Urinary Tract Symptoms in Myasthenia Gravis
title_full Lower Urinary Tract Symptoms in Myasthenia Gravis
title_fullStr Lower Urinary Tract Symptoms in Myasthenia Gravis
title_full_unstemmed Lower Urinary Tract Symptoms in Myasthenia Gravis
title_short Lower Urinary Tract Symptoms in Myasthenia Gravis
title_sort lower urinary tract symptoms in myasthenia gravis
topic myasthenia gravis
lower urinary tract symptom
quality of life
overactive bladder
url https://www.karger.com/Article/FullText/514825
work_keys_str_mv AT fuyukitateno lowerurinarytractsymptomsinmyastheniagravis
AT ryujisakakibara lowerurinarytractsymptomsinmyastheniagravis
AT yosukeaiba lowerurinarytractsymptomsinmyastheniagravis